Your browser doesn't support javascript.
Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants.
Pegu, Amarendra; O'Connell, Sarah E; Schmidt, Stephen D; O'Dell, Sijy; Talana, Chloe A; Lai, Lilin; Albert, Jim; Anderson, Evan; Bennett, Hamilton; Corbett, Kizzmekia S; Flach, Britta; Jackson, Lisa; Leav, Brett; Ledgerwood, Julie E; Luke, Catherine J; Makowski, Mat; Nason, Martha C; Roberts, Paul C; Roederer, Mario; Rebolledo, Paulina A; Rostad, Christina A; Rouphael, Nadine G; Shi, Wei; Wang, Lingshu; Widge, Alicia T; Yang, Eun Sung; Beigel, John H; Graham, Barney S; Mascola, John R; Suthar, Mehul S; McDermott, Adrian B; Doria-Rose, Nicole A; Arega, Jae; Beigel, John H; Buchanan, Wendy; Elsafy, Mohammed; Hoang, Binh; Lampley, Rebecca; Kolhekar, Aparna; Koo, Hyung; Luke, Catherine; Makhene, Mamodikoe; Nayak, Seema; Pikaart-Tautges, Rhonda; Roberts, Paul C; Russell, Janie; Sindall, Elisa; Albert, Jim; Kunwar, Pratap; Makowski, Mat.
  • Pegu A; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
  • O'Connell SE; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
  • Schmidt SD; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
  • O'Dell S; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
  • Talana CA; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
  • Lai L; Department of Pediatrics, Division of Infectious Disease, Emory Vaccine Center, Yerkes National Primate Research Center, Emory University School of Medicine, Atlanta, GA 30322, USA.
  • Albert J; Emmes Company, Rockville, MD 20850, USA.
  • Anderson E; Department of Pediatrics, Division of Infectious Disease, Emory Vaccine Center, Yerkes National Primate Research Center, Emory University School of Medicine, Atlanta, GA 30322, USA.
  • Bennett H; Moderna, Inc., Cambridge, MA 02139, USA.
  • Corbett KS; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
  • Flach B; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
  • Jackson L; Kaiser Permanente Washington Health Research Institute, Seattle, WA 98101, USA.
  • Leav B; Moderna, Inc., Cambridge, MA 02139, USA.
  • Ledgerwood JE; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
  • Luke CJ; Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
  • Makowski M; Emmes Company, Rockville, MD 20850, USA.
  • Nason MC; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
  • Roberts PC; Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
  • Roederer M; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
  • Rebolledo PA; Hope Clinic, Department of Medicine, Emory University School of Medicine, Decatur, GA 30030, USA.
  • Rostad CA; Department of Pediatrics, Division of Infectious Disease, Emory Vaccine Center, Yerkes National Primate Research Center, Emory University School of Medicine, Atlanta, GA 30322, USA.
  • Rouphael NG; Hope Clinic, Department of Medicine, Emory University School of Medicine, Decatur, GA 30030, USA.
  • Shi W; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
  • Wang L; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
  • Widge AT; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
  • Yang ES; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
  • Beigel JH; Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
  • Graham BS; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
  • Mascola JR; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
  • Suthar MS; Department of Pediatrics, Division of Infectious Disease, Emory Vaccine Center, Yerkes National Primate Research Center, Emory University School of Medicine, Atlanta, GA 30322, USA.
  • McDermott AB; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
  • Doria-Rose NA; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Science ; 373(6561): 1372-1377, 2021 Sep 17.
Article in English | MEDLINE | ID: covidwho-1356908
ABSTRACT
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mutations may diminish vaccine-induced protective immune responses, particularly as antibody titers wane over time. Here, we assess the effect of SARS-CoV-2 variants B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), B.1.429 (Epsilon), B.1.526 (Iota), and B.1.617.2 (Delta) on binding, neutralizing, and angiotensin-converting enzyme 2 (ACE2)­competing antibodies elicited by the messenger RNA (mRNA) vaccine mRNA-1273 over 7 months. Cross-reactive neutralizing responses were rare after a single dose. At the peak of response to the second vaccine dose, all individuals had responses to all variants. Binding and functional antibodies against variants persisted in most subjects, albeit at low levels, for 6 months after the primary series of the mRNA-1273 vaccine. Across all assays, B.1.351 had the lowest antibody recognition. These data complement ongoing studies to inform the potential need for additional boost vaccinations.
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antibodies, Neutralizing / COVID-19 Vaccines / SARS-CoV-2 / Antibodies, Viral Type of study: Randomized controlled trials Topics: Vaccines / Variants Limits: Adolescent / Adult / Aged / Humans / Middle aged / Young adult Language: English Journal: Science Year: 2021 Document Type: Article Affiliation country: Science.abj4176

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antibodies, Neutralizing / COVID-19 Vaccines / SARS-CoV-2 / Antibodies, Viral Type of study: Randomized controlled trials Topics: Vaccines / Variants Limits: Adolescent / Adult / Aged / Humans / Middle aged / Young adult Language: English Journal: Science Year: 2021 Document Type: Article Affiliation country: Science.abj4176